We have evaluated the impact of pretreatment somatic EGFR T790M mutations , TP53 mutations , and Bcl-2 interacting mediator of cell death ( BCL2L11 , also known as BIM ) mRNA expression in 95 patients with EGFR-mutant non-small-cell lung cancer ( NSCLC ) included in the EURTAC trial ( trial registration : NCT00446225 ) .